Annovis Bio, Inc.
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$28.9M
- Total assets
- $21.1M
- Market cap
- $80.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $29.7M
- Operating income
- -$29.7M
- Income tax
- $0
- Net income
- -$28.9M
- EPS (basic)
- $-1.40
- EPS (diluted)
- $-1.40
Balance sheet
- Total assets
- $21.1M
- Current assets
- $21.1M
- Total liabilities
- $4.2M
- Current liabilities
- $3.6M
- Shareholders’ equity
- $16.9M
Cash flow
- Operating cash flow
- -$25.6M
- Investing cash flow
- -$9.0M
- Financing cash flow
- $34.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $80.4M
- EPS (diluted)
- $-1.4
- Shares outstanding
- 44.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 29, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $28.9M in FY2025.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Annovis Bio, Inc..
Write a review
News about Annovis Bio, Inc.
News & sentiment via Polygon.io
